LUNG Pulmonx

Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021

Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Tuesday, November 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 9545716. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at .

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit . For more information on the company, please visit .

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact

Brian Johnston

Gilmartin Group



EN
26/10/2021

Underlying

LUNGPulmonx

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pulmonx

 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx Reports Third Quarter 2025 Financial Results

Pulmonx Reports Third Quarter 2025 Financial Results REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue in the third quarter of 2025...

16h / 2m 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx Announces Management Transition and Preliminary Third Quarter ...

Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025 Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be ap...

October 27, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Report Third Quarter 2025 Financial Results on October 29, ...

Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025 REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. Parties interested in participating by phone should register us...

October 15, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx to Participate in September Investor Conferences

Pulmonx to Participate in September Investor Conferences REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceFormat: Fireside Chat and 1x1 meetingsDate: Thursday, September 4 at 1:30 pm PT/ 4:30 pm ETLocation: Boston, MAWebcast Link: Lake Street Best Ideas Growth (BIG9) ConferenceFormat: 1x1 meetingsDate: Thursday, September 11Locati...

August 26, 2025 1 EN
 PRESS RELEASE
Free
LUNG PULMONX

Pulmonx Reports Second Quarter 2025 Financial Results

Pulmonx Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2025 ended June 30, 2025. Recent Highlights Achieved worldwide revenue of $23.9 million in the second quarter of 2025, a 15% increase over the same period last year and an increase of 13% on a constant currency basisDelivered $9.1 million in international revenue in the second quart...

July 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch